Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00133289 · ClinicalTrials.gov registry record · Phase 4

ULTRA Study for Pacemaker Patients

A Phase 4 study of Bradycardia, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 4
Development phase
950
Enrollment target
1
Study location

NCT00133289 is a Phase 4 study of Bradycardia that has completed, run by Boston Scientific Corporation. The registered enrollment target is 950 participants, below the 4,380-participant average among 29 other Bradycardia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00133289, a Phase 4 study of Bradycardia, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 4
Development phase
950 participants
Enrollment target
1
Study location

Study Summary

The ULTRA study will assess the difference in average ventricular voltage output for pacemaker patients randomized to Automatic Capture feature ON versus patients randomized to Automatic Capture feature OFF.

Conditions Studied

Interventions

  • DEVICE Pacemaker with Automatic Capture

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 950 participants
Start Date 2005-07
Est. Completion 2007-06
Phase Phase 4

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00133289

The ClinicalTrials.gov registry entry for NCT00133289 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 950 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,380-participant average among 29 other Bradycardia trials with a reported enrollment target (78% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Pacemaker with Automatic Capture is the first listed.

NCT00133289 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00133289 about?

NCT00133289 is a clinical study titled "ULTRA Study for Pacemaker Patients". The ULTRA study will assess the difference in average ventricular voltage output for pacemaker patients randomized to Automatic Capture feature ON versus patients randomized to Automatic Capture feature OFF.

What is the current status of trial NCT00133289?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 950 participants. The study started on 2005-07. Estimated completion is 2007-06.

What conditions does trial NCT00133289 study?

This clinical trial studies the following conditions: Bradycardia.

What interventions are being tested in trial NCT00133289?

The interventions under investigation include: Pacemaker with Automatic Capture (DEVICE).

Who is sponsoring clinical trial NCT00133289?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00133289 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bradycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.